Clinical trial Recruiting at 1 site Observational Ages 18 and up

Registry of Valvular Heart Disease in Hospitalized Adults in China

Official title: A Prospective, Single-center,Registry Study of Chinese Hospitalized Adult Patients With Valvular Heart Disease

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT03011697 · Data updated 2026-11-12

This study is trying to gather information about adults in China who are hospitalized with valvular heart disease to better understand how common it is, how it's treated, and what the outcomes are.

More Valvular Heart Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment10000 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedFebruary 1, 2017
Main results expectedDecember 31, 2026
Study endsDecember 31, 2027
Registry record updatedJuly 15, 2021
Trial IDNCT03011697 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are hospitalized adults over 18 years old with moderate or severe valvular heart disease as defined by echocardiographic criteria.

Probably not a fit

Patients with mild valvular heart disease or those not hospitalized may not receive benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to gather contemporary data on the prevalence, characteristics, risk stratification, cost-effectiveness, treatments, and prognosis of hospitalized adult patients with valvular heart disease in China. Given the increasing frequency of valvular heart disease, particularly among the aging population, this study seeks to address the gaps in understanding its impact in developing countries. By focusing on hospitalized patients over 18 years old with moderate or severe valvular conditions, the study will provide valuable insights into the management and outcomes of this patient population.

Why it matters

Potential benefit: If successful, this study could enhance the understanding and treatment of valvular heart disease in Chinese patients, leading to improved patient outcomes.

How similar studies have gone: While similar studies have been conducted, this specific observational cohort approach focusing on the Chinese population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Hospitalized patients over 18 years old meet one of the following conditions.

1. moderate or above valvular heart disease as defined by echocardiography: 1.1 Aortic stenosis, moderate or above, or valve area ≤1.5cm2, or maximal jet velocity ≥3.0m/sec, or mean pressure gradient ≥20mmHg, 1.2 Aortic regurgitation, moderate or above, or jet width ≥25% of left ventricular outflow tract, or regurgitant volume ≥30ml/beat, or regurgitant fraction ≥30%, 1.3 Mitral stenosis, moderate or above, or valve area ≤2.0cm2, 1.4 Mitral regurgitation, moderate or above, or effective regurgitant orifice ≥0.2cm2, or regurgitant volume ≥30ml/beat, or regurgitant fraction ≥30%, 1.5 Tricuspid stenosis, moderate or above, or valve area ≤1.0cm2, 1.6 Tricuspid regurgitation, moderate or above, or central jet area ≥5.0cm2, 1.7 Pulmonic stenosis, moderate or above, or maximal jet velocity \>4m/sec, 1.8 Pulmonic regurgitation, moderate or above,
2. Patients who had undergone any operation on a cardiac valve (percutaneous balloon commissurotomy, valve repair, valve replacement, transcatheter aortic valve implantation),
3. Diagnosis of endocarditis as assessed by Duke criteria.

Exclusion Criteria:

1. Patients cannot be followed up for any reasons.
2. Patients in critical condition may be die in one year.
3. Patients have been enrolled in this study.

Where it's running

  • 2nd Affiliated Hospital, School of Medicine at Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Wang Jian-an, MD,PhD — Second Affiliated Hospital, Zhejiang University, School of Medicine
  • Study coordinator: Liu Xianbao, MD
  • Email: liuxb2009@hotmail.com
  • Phone: +86-13857173887

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.